Literature DB >> 25929234

Aminopeptidase N activity predicts 5-year survival in colorectal cancer patients.

Begoña Sanz1, Itxaro Perez, Maider Beitia, Peio Errarte, Ainhoa Fernández, Lorena Blanco, Itziar Estalella, Alberto Loizate, Jon Irazusta, José I López, Gorka Larrinaga.   

Abstract

BACKGROUND: Aminopeptidase N (APN; EC 3.4.11.2) is a membrane dimeric metallopeptidase involved in differentiation, development, and proliferative processes of several tissues. Recent studies have demonstrated the increased expression and activity of this enzyme in several cancers. However, there are no available data about the impact of this peptidase in the biological aggressiveness and the survival of colorectal cancer (CRC) patients.
METHODS: The activity and mRNA expression of APN in tumor tissue (n = 81) and plasma (n = 40) of patients with CRC of low and high grades and stages were prospectively analyzed by fluorimetric and quantitative reverse transcriptase-polymerase chain reaction methods. Data obtained in adenoma and CRC were compared with those from the surrounding normal mucosa. Classic clinical and pathological parameters were stratified following APN data and analyzed for 5-year survival.
RESULTS: mRNA levels of APN (ANPEP) were lower in colorectal adenomas and adenocarcinomas than in the surrounding uninvolved mucosa (Kruskal-Wallis, P < 0.001). Aminopeptidase N activity in CRC tissue was higher in patients with better overall survival (log-rank P < 0.05, Cox analysis P < 0.05). By contrast, higher plasmatic APN activity correlated with worse overall survival (log-rank P < 0.01, Cox analysis P < 0.05).
CONCLUSIONS: Aminopeptidase N activity in tissue and plasma from CRC patients is an independent prognostic factor of 5-year survival. The determination of APN activity levels in the plasma may be a safe, minimally invasive, and inexpensive way to define the aggressiveness of CRC in daily practice.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25929234     DOI: 10.1097/JIM.0000000000000199

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  7 in total

1.  Partition: a surjective mapping approach for dimensionality reduction.

Authors:  Joshua Millstein; Francesca Battaglin; Malcolm Barrett; Shu Cao; Wu Zhang; Sebastian Stintzing; Volker Heinemann; Heinz-Josef Lenz
Journal:  Bioinformatics       Date:  2020-02-01       Impact factor: 6.937

2.  CD13 is a useful tool in the differential diagnosis of meningiomas with potential biological and prognostic implications.

Authors:  Stefano Marletta; Claudio Luchini; Nicola Sperandio; Evelin Torresani; Alessandro Sorio; Ilaria Girolami; Aldo Scarpa; Albino Eccher; Claudio Ghimenton
Journal:  Virchows Arch       Date:  2022-02-25       Impact factor: 4.535

3.  Serum APN/CD13 as a novel diagnostic and prognostic biomarker of pancreatic cancer.

Authors:  Li Pang; Nan Zhang; Yan Xia; Dawei Wang; Guoqing Wang; Xiangwei Meng
Journal:  Oncotarget       Date:  2016-11-22

4.  Sex differences in the aging pattern of renin-angiotensin system serum peptidases.

Authors:  A Fernández-Atucha; A Izagirre; A B Fraile-Bermúdez; M Kortajarena; G Larrinaga; P Martinez-Lage; E Echevarría; J Gil
Journal:  Biol Sex Differ       Date:  2017-02-03       Impact factor: 5.027

5.  Altered expression of fibroblast activation protein-α (FAP) in colorectal adenoma-carcinoma sequence and in lymph node and liver metastases.

Authors:  Jon Danel Solano-Iturri; Maider Beitia; Peio Errarte; Julio Calvete-Candenas; María C Etxezarraga; Alberto Loizate; Enrique Echevarria; Iker Badiola; Gorka Larrinaga
Journal:  Aging (Albany NY)       Date:  2020-05-19       Impact factor: 5.682

6.  Computational study of novel natural inhibitors targeting aminopeptidase N(CD13).

Authors:  Junliang Ge; Zhongfeng Wang; Ye Cheng; Junan Ren; Bo Wu; Weihang Li; Xinhui Wang; Xing Su; Ziling Liu
Journal:  Aging (Albany NY)       Date:  2020-05-09       Impact factor: 5.682

Review 7.  Molecular Imaging of Aminopeptidase N in Cancer and Angiogenesis.

Authors:  Cynthia L Schreiber; Bradley D Smith
Journal:  Contrast Media Mol Imaging       Date:  2018-06-25       Impact factor: 3.161

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.